<DOC>
	<DOC>NCT00951275</DOC>
	<brief_summary>This single arm study will assess the effect of tocilizumab + DMARDs (Disease Modifying Anti-Rheumatic Drugs)on improvement of anemia and fatigue in patients with moderate to severe active rheumatoid arthritis. Eligible patients who have had an inadequate response to DMARDs will receive tocilizumab 8mg/kg iv every 4 weeks in combination with standard DMARDs, for 6 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; rheumatoid arthritis &gt;=6 months duration; DAS28&gt;=3.2; inadequate response to prior treatment with a stable dose (&gt;=8 weeks) of DMARD therapy. rheumatic autoimmune disease other than rheumatoid arthritis; history of or current inflammatory joint disease other than rheumatoid arthritis; unsuccessful treatment with an antiTNF agent; previous/concurrent treatment with any celldepleting therapies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>